Omalizumab and malignancy: Interim results from the EXCELS study

M. Eisner, M. Miller, W. Chou, A. Rahmaoui, M. Bradley (South San Francisco, United States Of America)

Source: Annual Congress 2011 - Asthma management and response
Session: Asthma management and response
Session type: Thematic Poster Session
Number: 3954
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. Eisner, M. Miller, W. Chou, A. Rahmaoui, M. Bradley (South San Francisco, United States Of America). Omalizumab and malignancy: Interim results from the EXCELS study. Eur Respir J 2011; 38: Suppl. 55, 3954

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Eligibility for mepolizumab, omalizumab and reslizumab in the EU population: The IDEAL study
Source: International Congress 2016 – Asthma: treatment, disease control, and quality of life
Year: 2016


Multivariate cluster analysis of immunopathological and clinical data from the U-BIOPRED severe asthma study: Preliminary results
Source: International Congress 2015 – New insights into lung disease pathogenesis
Year: 2015

Evaluation of roflumilast in COPD patients in a real-world European setting: results from the PROFILE EU study
Source: International Congress 2017 – What is new in COPD management and prognosis: findings from large studies?
Year: 2017


Late Breaking Abstract - International, prospective real-world study of mepolizumab in patients with severe asthma at one year: REALITI-A
Source: Virtual Congress 2021 – Advances in asthma treatment
Year: 2021


Interim analysis of a prospective study investigating oral corticosteroid (OCS) use in omalizumab treated severe allergic asthma patients: APEX II study
Source: International Congress 2014 – Intervening in allergic asthma
Year: 2014


Effectiveness of omalizumab in Canadian patients with allergic asthma: A retrospective study.
Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside
Year: 2017

ADEPT, airway disease endotyping for personalized treatment: Interim analysis of asthma patients
Source: Annual Congress 2013 –Novel drugs and biomarkers in respiratory medicine
Year: 2013

An Italian, observational, multicentre trial to describe treatment management in COPD patients: Preliminary results of the MISTRAL study
Source: International Congress 2014 – Monitoring airway diseases with lung function tests
Year: 2014


Preliminary results from the laboratory phase of ECRHSIII in Melbourne
Source: Annual Congress 2013 –Epidemiology of asthma
Year: 2013

Clinical course of IPF Italian patients during 12-month of observation: results from the FIBRONET observational study
Source: International Congress 2019 – Interstitial lung disease registries
Year: 2019

Asthma exacerbations with long-term follow-up: a retrospective study
Source: International Congress 2019 – Clinical approach to asthma management
Year: 2019

The EDUCA (Elderly and Device Use in Chronic Asthma) multicentre Italian study on the assessment of errors and satisfaction in using the inhalers in elderly asthmatics: Preliminary results.
Source: International Congress 2017 – Inhalers and their use
Year: 2017

Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis
Source: Eur Respir J, 56 (4) 2000151; 10.1183/13993003.00151-2020
Year: 2020



An Italian, observational, multicenter trial in female COPD patients: Preliminary data on the women reality in the MISTRAL study
Source: International Congress 2014 – Clinical assessment of airway diseases
Year: 2014


The Spanish national clinical audit on COPD exacerbations. Results of a pilot study: main outcomes
Source: Annual Congress 2008 - Prognosis in COPD
Year: 2008


Patient burden of not well-controlled asthma: results of a European survey
Source: Annual Congress 2009 - Asthma treatment and control strategies in primary care
Year: 2009



Attention to ACOS in patients with asthma and COPD:Results from a national- multicentered study
Source: International Congress 2017 – Many faces of asthma and allergies
Year: 2017

Stop omalizumab: a multicenter follow up study after discontinuation in pediatric patients with severe asthma
Source: Virtual Congress 2021 – Paediatric allergic asthma: novel therapeutics and monitoring approaches
Year: 2021


Health and functional status of tiotropium/olodaterol-treated patients with COPD: results from the AERIAL® non-interventional study
Source: ERJ Open Res, 7 (3) 00004-2021; 10.1183/23120541.00004-2021
Year: 2021



Patients in randomized clinical trials of bronchiectasis are only partially representative of clinical practice: A European cohort study
Source: International Congress 2015 – Bronchiectasis and NTM infections: clinical aspects and research outlook
Year: 2015